Pfizer vaccine effective against South African coronavirus variant, preliminary data point out –

Pfizer vaccine effective against South African coronavirus variant, preliminary data point out –
Pfizer vaccine effective against South African coronavirus variant, preliminary data point out –
Pfizer announced that its Covid-19 vaccine, developed in partnership with the German biotechnology company BioNTech, is effective against the coronavirus variant first identified in South Africa (B.1.351).

In a statement published on Thursday (1st), the company states that in the South African arm of the study carried out with the immunizer, nine cases of Covid-19 were recorded with symptoms among the 800 participants – all records of the disease occurred in the group placebo (who did not receive the vaccine).
After a genetic sequencing of the viruses that caused these infections, the scientists concluded that six of them were of the B.1.351 lineage, which is now prevalent in the country. The data indicate 100% protection against the variant, but these are preliminary figures and the sample is considered small to allow definitive conclusions.

“These data confirm previous results that demonstrated that the BNT162b2 vaccine [nome do imunizante] induces a robust response of neutralizing antibodies of variant B.1.351 ”, says the company in the note.

Pfizer and BioNTech also announced that the BNT162b2 vaccine remains highly effective (91.3%) against the coronavirus even after six months after the second dose has been applied. The result comes from the analysis of data from more than 12 thousand participants vaccinated in the study with the immunizer.

The companies claim that no serious security problems were detected in the more than 44,000 participants in the study. The BNT162b2 vaccine is used in the United States and Israel, among other countries.

On Monday (29), the CDC (United States Center for Disease Control and Prevention) confirmed that Pfizer / BioNTech and Moderna vaccines against Covid-19, both based on the messenger RNA (mRNA) technique, have an efficacy of 90% or more in a study that takes into account data on the use of the immunizer in the real world, that is, outside of clinical tests.

According to the CDC, the first dose of one of the two vaccines was enough to reduce the chances of being infected by the virus causing Covid-19 by 80% from two weeks after the injection. Symptomatic and asymptomatic infections were evaluated in nearly 4,000 participants from six US states.

The CDC study included health professionals and workers considered essential, the first to receive injections and the most susceptible to infection.

The mRNA vaccines were the great scientific achievement of 2020. These immunizers carry the genetic code of the virus that contains the instructions for cells in the body to produce proteins that stimulate the body’s immune response against the pathogen.

As a rule, all vaccines need to carry some form of virus identification that serves to alert the immune system against an invader and initiate the production of protective molecules.

Vaccines simulate an infection to trick the body into inducing the immune response to form. Thus, when the body finds the active virus, capable of generating disease, the body already has ready defenses.

Get the latest news delivered to your inbox

Follow us on social media networks

PREV Chocolate is good for the eyes
NEXT Alagoas receives 120 thousand new doses of vaccines against Covid this Thursday